These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
339 related articles for article (PubMed ID: 21074068)
1. Signaling through OX40 enhances antitumor immunity. Jensen SM; Maston LD; Gough MJ; Ruby CE; Redmond WL; Crittenden M; Li Y; Puri S; Poehlein CH; Morris N; Kovacsovics-Bankowski M; Moudgil T; Twitty C; Walker EB; Hu HM; Urba WJ; Weinberg AD; Curti B; Fox BA Semin Oncol; 2010 Oct; 37(5):524-32. PubMed ID: 21074068 [TBL] [Abstract][Full Text] [Related]
2. The Immune Checkpoint Modulator OX40 and Its Ligand OX40L in NK-Cell Immunosurveillance and Acute Myeloid Leukemia. Nuebling T; Schumacher CE; Hofmann M; Hagelstein I; Schmiedel BJ; Maurer S; Federmann B; Rothfelder K; Roerden M; Dörfel D; Schneider P; Jung G; Salih HR Cancer Immunol Res; 2018 Feb; 6(2):209-221. PubMed ID: 29321210 [TBL] [Abstract][Full Text] [Related]
3. OX40 ligand expressed in glioblastoma modulates adaptive immunity depending on the microenvironment: a clue for successful immunotherapy. Shibahara I; Saito R; Zhang R; Chonan M; Shoji T; Kanamori M; Sonoda Y; Kumabe T; Kanehira M; Kikuchi T; So T; Watanabe T; Takahashi H; Iwabuchi E; Tanaka Y; Shibahara Y; Sasano H; Ishii N; Tominaga T Mol Cancer; 2015 Feb; 14():41. PubMed ID: 25744203 [TBL] [Abstract][Full Text] [Related]
4. Targeting OX40 and OX40L for the treatment of autoimmunity and cancer. Redmond WL; Weinberg AD Crit Rev Immunol; 2007; 27(5):415-36. PubMed ID: 18197805 [TBL] [Abstract][Full Text] [Related]
5. Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity. Redmond WL; Linch SN; Kasiewicz MJ Cancer Immunol Res; 2014 Feb; 2(2):142-53. PubMed ID: 24778278 [TBL] [Abstract][Full Text] [Related]
6. Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein. Oberst MD; Augé C; Morris C; Kentner S; Mulgrew K; McGlinchey K; Hair J; Hanabuchi S; Du Q; Damschroder M; Feng H; Eck S; Buss N; de Haan L; Pierce AJ; Park H; Sylwester A; Axthelm MK; Picker L; Morris NP; Weinberg A; Hammond SA Mol Cancer Ther; 2018 May; 17(5):1024-1038. PubMed ID: 29545330 [TBL] [Abstract][Full Text] [Related]
9. Control of immunity by the TNFR-related molecule OX40 (CD134). Croft M Annu Rev Immunol; 2010; 28():57-78. PubMed ID: 20307208 [TBL] [Abstract][Full Text] [Related]
10. OX40/OX40 ligand and its role in precision immune oncology. Thapa B; Kato S; Nishizaki D; Miyashita H; Lee S; Nesline MK; Previs RA; Conroy JM; DePietro P; Pabla S; Kurzrock R Cancer Metastasis Rev; 2024 Sep; 43(3):1001-1013. PubMed ID: 38526805 [TBL] [Abstract][Full Text] [Related]
11. PLGA-nanoparticle mediated delivery of anti-OX40 monoclonal antibody enhances anti-tumor cytotoxic T cell responses. Chen M; Ouyang H; Zhou S; Li J; Ye Y Cell Immunol; 2014 Feb; 287(2):91-9. PubMed ID: 24487032 [TBL] [Abstract][Full Text] [Related]
12. Enhancing the Generation of Eomes Emerson DA; Rolig AS; Redmond WL Cancer Immunol Res; 2021 Apr; 9(4):430-440. PubMed ID: 33593794 [TBL] [Abstract][Full Text] [Related]
13. The small molecule TGF-β signaling inhibitor SM16 synergizes with agonistic OX40 antibody to suppress established mammary tumors and reduce spontaneous metastasis. Garrison K; Hahn T; Lee WC; Ling LE; Weinberg AD; Akporiaye ET Cancer Immunol Immunother; 2012 Apr; 61(4):511-21. PubMed ID: 21971588 [TBL] [Abstract][Full Text] [Related]
14. OX40 signaling directly triggers the antitumor effects of NKT cells. Zhou D J Clin Invest; 2007 Nov; 117(11):3169-72. PubMed ID: 17975660 [TBL] [Abstract][Full Text] [Related]
15. The significance of OX40 and OX40L to T-cell biology and immune disease. Croft M; So T; Duan W; Soroosh P Immunol Rev; 2009 May; 229(1):173-91. PubMed ID: 19426222 [TBL] [Abstract][Full Text] [Related]
16. The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy. Moran AE; Kovacsovics-Bankowski M; Weinberg AD Curr Opin Immunol; 2013 Apr; 25(2):230-7. PubMed ID: 23414607 [TBL] [Abstract][Full Text] [Related]
17. OX40 Agonist Tumor Immunotherapy Does Not Impact Regulatory T Cell Suppressive Function. Polesso F; Sarker M; Weinberg AD; Murray SE; Moran AE J Immunol; 2019 Oct; 203(7):2011-2019. PubMed ID: 31434709 [TBL] [Abstract][Full Text] [Related]
18. OX40 signaling is involved in the autoactivation of CD4 Jiang J; Liu C; Liu M; Shen Y; Hu X; Wang Q; Wu J; Wu M; Fang Q; Zhang X Arthritis Res Ther; 2017 Mar; 19(1):67. PubMed ID: 28320444 [TBL] [Abstract][Full Text] [Related]
19. The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy. Buchan SL; Rogel A; Al-Shamkhani A Blood; 2018 Jan; 131(1):39-48. PubMed ID: 29118006 [TBL] [Abstract][Full Text] [Related]
20. Ligand-Blocking and Membrane-Proximal Domain Targeting Anti-OX40 Antibodies Mediate Potent T Cell-Stimulatory and Anti-Tumor Activity. Zhang P; Tu GH; Wei J; Santiago P; Larrabee LR; Liao-Chan S; Mistry T; Chu ML; Sai T; Lindquist K; Long H; Chaparro-Riggers J; Salek-Ardakani S; Yeung YA Cell Rep; 2019 Jun; 27(11):3117-3123.e5. PubMed ID: 31189099 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]